Track 5: Patient Engagement
This track addresses meaningful patient engagement in medical product development, from early product development, and approval, through maintenance phases. It focuses on important questions for all stakeholders, including:
- How do we meaningfully engage patients and incorporate their voices into decision-making throughout the medical product lifecycle?
- How do we become truly patient- (and people-) centric in our approach?
- How do we operationalize patient-centric approaches in our day-to-day work?
- How can we measure the effectiveness of our efforts, both for patient outcomes and to meet the needs of other stakeholders such as industry and regulatory decision-makers?
- What have we learned that can be used to drive more meaningful patient engagement?
- How do stakeholders best work together to leverage their collective power and expertise to promote meaningful involvement of patients?
Sessions in Patient Engagement
Sunday, June 14 | Short Courses
Monday, June 15
- Patients First! How FDA is Making Patients a Priority
- Engaging Patients to Support the Modernization of ClinicalTrials.gov
Tuesday, June 16
- Qualitative, Quantitative, and Mixed Method Approaches to Capture the Patient Experience
- Engaging Caregivers in Research and Medical Product Development
Wednesday, June 17
- Global Rare Disease Town Hall
- Optimizing Communication with Patients to Support Meaningful Feedback into the Research Process
Thursday, June 18
- Incorporating Patient Input into Medical Product Development and the US Food and Drug Administration’s Decision-Making
- Patient Preferences in the Medical Product Lifecycle: Evolving Uses, Stakeholder Considerations, and Applications
- Communicate and Co-Create with Patients Across the Medicines Development Lifecycle: Principles and Best Practices
- Impact Patient-Centered Initiatives in Clinical Trial Design and Execution
- The DEEP Model: Long-Term Commitment to Partnering with Patients
- Global Commission Harnessing Cutting-Edge Technology to Accelerate Diagnosis of Rare Diseases in Children
- Setting a Strategic Foundation for Mutually Beneficial Collaborations Between Industry and Patient Organizations
Who is This Track Designed For?
Professionals involved in: patient affairs, patient advocacy, patient groups, patient support services, medical affairs (including CMOs and MSLs), clinical trial design and optimization, clinical research and operations, regulatory affairs, regulatory agency, corporate and government affairs, safety and pharmacovigilance, outcomes research, epidemiology, and Health Technology Assessment..